163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

Anthony T.c Chan ,M-J Ahn,S.K Kho,Chia‐Jui Yen ,Quan Sing Ng ,Priscilla B Caguioa ,H.F.V Lee,Sb Kim ,M.A.S Abdul Aziz,Roger K.c Ngan ,Ramona F Swaby ,Sanatan Saraf ,Nuttapong Ngamphaiboon ,Nopadol Soparattanapaisarn ,Ho Gwo Fuang ,R-L Hong,Wan Qin Chong ,Cheryl Ho ,L Wang,Lillian L Siu

doi:10.1016/j.annonc.2021.10.182

163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

Anthony T.c Chan , M-J Ahn + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.182

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
Citations: 1	License type: publisher-specific-oa

#Nasopharyngeal Cancer #Chemo In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pembro did not improve OS vs chemo in patients (pts) with platinum-pretreated R/M NPC in KEYNOTE-122 (NCT02611960), but it had manageable safety and fewer treatment-related AEs. HRQoL results are shown.

Full Text